Hydroxyurea is currently the only FDA-approved drug that ameliorates the pathophysiology of sickle cell anemia. Unfortunately, substantial interpatient variability in the pharmacokinetics (PK) of hydroxyurea may result in variation of the drug's efficacy. However, little is known about mechanisms that modulate hydroxyurea PK. Recent in vitro studies identifying hydroxyurea as a substrate for or...

While currently available continuous glucose monitoring (CGM) systems have continually improving accuracy that has revolutionized modern diabetes care, potential medication interferences are recognized for all CGM (1). For Dexcom systems, hydroxyurea was recently as an interfering substance can falsely elevate sensor (SG) readings (2), but the data demonstrating this interference not been previ...

BACKGROUND Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients' perceptions are poorly understood amongst adolescents and young adults (AYA). Study objectives were to: (1) examine patients' perceptions of SCD and hydroxyurea; and (2) explore the relationship...

background: myeloproliferative neoplasms (mpns) are clonal malignant diseases that represent a group of conditions including polycythemia vera (pv), essential thrombocythemia (et) and primary myelofibrosis (pmf). the aim of this study was to evaluate possible correlations between jak2v617f allele burden and clinicohematologic characteristics in iranian patients with mpns. we also aimed at deter...

background: hydroxyurea (hu) is a well known chemotherapeutic agent that has been used largely for various myeloproliferative diseases over the past 20 years. in β-thalassemia, the effect of hu is much less clear and remains controversial. this study was undertaken to describe the hematologic and clinical responses of thalassemia major and intermediate patients to hu treatment during 2 years. m...

In this issue of Blood, Ware and Helms report results from the Stroke With Transfusions Changing To Hydroxyurea (SWiTCH) study designed to determine whether hydroxyurea is as effective as transfusions in preventing recurrent strokes in children with sickle cell anemia. The finding of strokes in 7 of 67 children receiving hydroxyurea but none in 66 children who received transfusions led the auth...

Hydroxyurea inhibited the replication of bacteriophage T4 in Escherichia coli B. The concentration of hydroxyurea required to inhibit net deoxyribonucleic acid (DNA) synthesis 50% was about 50-fold less than that required in uninfected cells. Even in the presence of high hydroxyurea concentrations, phage DNA was readily synthesized from the products of breakdown of the E. coli DNA, and viable p...

The combination of imatinib mesylate and hydroxyurea provides a therapeutic benefit in patients with glioblastoma, although each drug is not effective when used alone. The increase of brain delivery of one or both drugs has been suggested to be a potential cause of this therapeutic benefit. The cross-influence of hydroxyurea and imatinib on their respective brain distribution was examined in mi...

Hydroxyurea is an effective com[»undin inhibiting the growth of a transplantable mammary tumor (HMC) in the Fischer rat, the inhibition being dose related and independent of the duration of treatment. Several compounds related to hydroxyurea were tested and compared to the parent compound. 1-Ethyl-lhydroxy urea and 1-methyl-l-hydroxyurea are more effective than hydroxyurea in causing inhibitio...